Proxy advisory firm Glass Lewis said Illumina’s CEO and board chairman shouldn’t be reelected to the board of directors. This provides a tactical victory to activist investor Carl Icahn in his battle with the company. (Endpoints News)

Boehringer Ingelheim said the side effects of its experimental obesity drug were consistent with rival GLP-1 based injectable drugs. Paola Casarosa, head of therapeutic areas at Boehringer Ingelheim, added that a larger follow-up trial in the third and last phase of drug testing was being prepared and that the two partners were discussing the trial design with key regulators across the world. (Reuters)

As U.S. drug shortages hit a five-year high and concerns mount about the safety of medicines, the Biden administration has quietly assembled a team to address chronic problems hurting America’s drug supply. The effort has intensified as Americans struggle to find common drugs like antibiotics and amid high-profile safety lapses like deadly eye drops. (Bloomberg)

A jury cleared Gilead Sciences of U.S. government allegations that it violated patents held by the Centers for Disease Control and Prevention on an HIV prevention drug. Jurors found that the government’s patent claims on the HIV prevention regimen called pre-exposure prophylaxis were not valid. (CNBC)

Biotechnology entrepreneur Gene Lay, the founder and CEO of BioLegend, Inc., made a $100 million donation to Brigham and Women’s Hospital — the largest donation in its history. The hospital said it plans to establish The Gene Lay Institute of Immunology and Inflammation. (